What Should We Expect From the Next Generation of Antiarrhythmic Drugs?

@article{Camm1999WhatSW,
  title={What Should We Expect From the Next Generation of Antiarrhythmic Drugs?},
  author={A. Camm and Y. G. Yap},
  journal={Journal of Cardiovascular Electrophysiology},
  year={1999},
  volume={10}
}
  • A. Camm, Y. G. Yap
  • Published 1999
  • Medicine
  • Journal of Cardiovascular Electrophysiology
The Next Generation of Antiarrhythmic Drugs. Five drugs currently constitute approximately 70% of the world market for antiarrhythmic medications. Since the publication of studies documenting that certain Class I drugs may increase mortality in high‐risk postinfarction patients, basic science and clinical studies have focused on Class III antiarrhythmic drugs. However, drugs that prolong repolarization and cardiac refractoriness are sometimes associated with potentially lethal torsades de… Expand
A Benefit-Risk Assessment of Class III Antiarrhythmic Agents
TLDR
Subgroup analyses of trials with amiodarone and dofetilide suggest that patients with atrial fibrillation may have a mortality reduction with these drugs, however, this needs to be tested in a prospective trial. Expand
Current Antiarrhythmic Drugs
  • B. Singh
  • Medicine
  • Journal of cardiovascular electrophysiology
  • 1999
TLDR
The objective of drug development should he the appropriate match between the substrate and an antiarrhythimic drug, which results in a spectrum of electrophysiologic properties that includes lack of rate or use dependency in terms of effect on repolarization and refractoriness of atrial and ventricular myocardium. Expand
A benefit–risk assessment of class III antiarrhythmic agents
TLDR
The benefits discussed include the ability to maintain sinus rhythm in persistent atrial fibrillation patients, and reducing the need for implantable cardioverter defibrillator shock/antitachycardia therapy, since no class III antiarrhythmic agents have proven survival benefit. Expand
Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs
TLDR
By virtue of its suppressant action on early afterdepolarizations and triggered activity in Purkinje fibers and M cells, the drug appears to have a powerful potential for reducing the torsadogenic proclivity of conventional class III antiarrhythmic compounds. Expand
Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias
TLDR
The more immediate and definable objective may include the control of arrhythmia symptoms and prolongation of survival, anticipation of side effects, and proarrhythmic reactions, and the longer-term objective is to study structure-activity relationships. Expand
Overview of trends in the control of cardiac arrhythmia: past and future.
  • B. Singh
  • Medicine
  • The American journal of cardiology
  • 1999
TLDR
The issue of whether the most effective medical therapy for controlling life-threatening ventricular arrhythmia might be a combination regimen rather than amiodarone or sotalol alone is raised, and future clinical trials should aim at defining the mosteffective ICD–drug combinations with single as well as multiple agents (including b-blockers) with endpoints including reduction of ICD shocks as as total mortality. Expand
Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
TLDR
Current opinion among physicians on the management of AF favors the restoration and maintenance of normal sinus rhythm, and recent interest has focused on the use of class III antiarrhythmic agents, such as amiodarone, sotalol, dofetilide, and azimilide in patients with AF and structural heart disease. Expand
New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation
TLDR
It is clear that the safety and effectiveness of the current antiarrhythmic drugs are largely suboptimal and that drugs more effective and, most important, devoid of systemic and cardiac untoward effects are strongly desirable. Expand
What niche will newer class III antiarrhythmic drugs occupy?
TLDR
The potential therapeutic niche of ibutilide, dofetilide, and azimilide in the control of cardiac arrhythmias forms the basis of this review. Expand
Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide
  • S. Doshi, B. Singh
  • Medicine
  • Journal of cardiovascular pharmacology and therapeutics
  • 2000
TLDR
Of the available anti-arrhythmic agents, beta-blockers, sotalol, and amiodarone are likely to remain the prototypical drugs of the future (3), although they are powerful sympathetic antagonists that act predominantly by prolonging the action potential duration. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 75 REFERENCES
Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
TLDR
A review of the pharmacology, including the pharmacokinetics and pharmacodynamics, of the most commonly used and investigated class III antiarrhythmic drugs, finding each has novel pharmacology that makes it applicable in specific clinical situations. Expand
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
TLDR
This open study evaluated the acute electrophysiologic effects, antiarrhythmic efficacy, and safety of different doses of intravenous dofetilide, a new class III drug, in 50 patients with sustained monomorphic ventricular tachycardia inducible by programmed electrical stimulation who had previously been unsuccessfully treated with 0 to 7 other drugs. Expand
Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination.
TLDR
Ibutilide, with a unique increase in atrial refractoriness, was more effective in conversion of atrial flutter than were propafenone and amiodarone. Expand
Azimilide dihydrochloride, a novel antiarrhythmic agent.
TLDR
Preclinical and clinical studies indicate that azimilide prolongs cardiac refractory period in a dose-dependent manner, as manifested by increases in action potential duration, QTc interval, and effective refractor period. Expand
Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia‐dependent arrhythmias
TLDR
The antiarrhythmic efficacy of RSD1000 and RSD1019 against ventricular arrhythmias induced by myocardial ischaemia were investigated in rats and additional experiments were performed in rabbits and nonhuman primates to rule out species‐specific drug actions. Expand
An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985.
TLDR
The use of antiarrhythmic drug therapy in patients resuscitated from prehospital ventricular fibrillation should be regarded as not only unproved, but potentially hazardous, and should probably be restricted to testing in randomized clinical trials. Expand
Dofetilide, A Novel Class III Antiarrhythmic Agent
TLDR
Pharmacodynamic data demonstrate dose- and concentration-dependent effects on myocardial repolarization as evidenced by prolongations of the QTC interval, supporting the contention that dofetilide is a highly selective class III antiarrhythmic agent. Expand
Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease. Ibutilide Investigators.
TLDR
Ibutilide prolongs ventricular repolarization in human beings and demonstrates efficacy in suppressing inducible monomorphic VT. Expand
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
TLDR
Three class III antiarrhythmic drugs may potentially be useful for the prevention and termination of atrial flutter and fibrillation through their inhibitory action on IK.ACh by the blockade of the atrial muscarinic receptors, whereas E-4031 and MS-551 may inhibit the current not only by blocking the mus carinic receptors but also by depressing the function of the K+ channel itself and/or G proteins. Expand
Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter.
TLDR
Analysis of a 3-month follow-up study showed that patients receiving ibutilide had similar outcomes compared with patients receiving placebo, and one placebo-treated patient died. Expand
...
1
2
3
4
5
...